Cookies on this website We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings. Continue Log in HOME ABOUT US RESEARCH PEOPLE STUDY WITH US VOLUNTEER CONTACT JOBS ENGAGE Search Oxford vaccine reaches two billion dose milestone University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines. Read more UPDATE ON COVID-19 VACCINE TRIAL For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.web.ox.ac.uk/. SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible. If you are interested in supporting this effort, please make a gift here. SEMINARS The Human Immunomics Initiative: Decoding the human immune system to accelerate development of vaccines and immunotherapies for major infectious diseases and cancers Monday, 06 December 2021, 3pm to 4pm LATEST PUBLICATIONS AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire Journal article Swanson PA. et al, (2021), Science Translational Medicine, 13 Correction to: Repertoire analysis of γδ T cells in the chicken enables functional annotation of the genomic region revealing highly variable pan-tissue TCR gamma V gene usage as well as identifying public and private repertoires. Journal article Dixon R. et al, (2021), BMC Genomics, 22 COVID OUTBREAK The University moved to Business Continuity Plan (BCP) Level 1 on Monday 6 September, enabling all staff to return to working on site. Please refer to our Health page for details of the University’s updated health guidance The hard work and swift adaptability of staff during the pandemic has ensured continuity for our students and researchers, and allowed the University to continue to succeed through what has been a very challenging period. The move to BCP Level 1 brings the University in line with Step 4 of the UK government’s roadmap, allowing for in-person learning and assessment wherever possible, a return to working on site for all staff, and increased public access to University and college facilities. It also means the removal of most COVID-19 restrictions in place at the University. PUBLIC ENGAGEMENT Tweets by The Jenner Institute COVID-19 RESPONSE - Protect our community - Protect the vulnerable - Protect yourself To find out more about the University's COVID-19 response and measures of protection: © 2021 The Jenner Institute Laboratories, ORCRB, Roosevelt Drive, Oxford OX3 7DQ Home Site Map Contact Freedom of Information Privacy Policy Copyright Accessibility Medical Sciences Division Oxford University @NDMOxford @JennerInstitute @vaccinetrials Jenner Institute Vaccine trials